View the oral presentations from the SGO 2020 Annual Meeting that were not part of the live webinar series in Spring 2020. 

• A first in-human proof-of-concept trial of intravaginal artesunate to treat cervical - C. Trimble
• Age matters when predicting overall survival benefit of chemoradiation vs. radiation
• A high-depth multi-omics analysis of clinically defined subsets of high-grade serous ovarian cancer - A. Sood
• Anti-tumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo - J. Ray
• A Phase IB study of navicixizumab & weekly paclitaxel in heavily pre-treated platinum resistant ovarian, primary peritoneal or fallopian tube cancer - K Moore
• A Phase IB Trial of Pacitaxel and Carboplatin + Galunisertib in Patients with Gynecologic Carcinosarcoma
• A Phase III randomized controled trial of prophylactic negative pressure wound therapy in post-operative incision management
• AVB-S6-500, a receptor tyrosine kinase AXL inhibitor, has improved therapeutic efficacy in combination with bevacizumab in uterine serous cancer - M. Toboni
• Behavioral weight loss intervention effectiveness in gynecologic oncology clinics - A. Zamorano
• Camrelizumab plus apatinib in patients with advanced cervical cancer - C Lan
• Compensation differences in Gynecologic Oncology
• Demicizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal
• Increased physical activity promotes CD8+ lymphocyte infiltration and improves survival in a murine model of ovarian cancer - S. Lynam
• Initial findings from a prospective, large scale patient reported outcomes program in patients with gynecologic malignancy - R. Sisodia
• Laparoscopic Interval Debulking Surgery for Advanced Ovarian Cancer - Jorgensen
• Less guessing, more evidence in identifying patients least fit for cytoreductive surgery - D. Narasimhulu
• Modifying risk factors for anastomotic leak in gynecologic oncology surgery - V. Manzina
• Multimodality algorithm to improve outcomes in patients receiving upfront surgical treatment for advanced ovarian cancer: a memorial sloan kettering team ovary initiative - A. Straubhar
• Out-of-pocket costs for PARP Inhibitor Treatment
• Perception and acceptability of human papillomavirus (HPV) vaccination among women presenting for cervical cancer (CxCA) screening in northern Tanzania - J. Maher
• Preliminary Prospective Quality of Life and Clinical Outcomes using an Opiate Sparing Enhanced Recovery Protocol - Kuznicki
• Relapse vs Chemotherapy Resistance after First-Line Single-Agent Chemotherapy in Patients with Low Risk Gestational Trophoblastic Neoplasia
• Risk factors for unplanned readmission due to uncontrolled symptoms or minor complications after surgery for gynecologic cancer - A. Pyrzak
• Same-day discharge for gynecologic oncology patients undergoing minimally invasive hysterectomy: Feasibility, safety, factors associated with admission and post-operative adverse events - A. Wield
• The impact of frailty on readmission morbidity and mortality after surgery for endometrial cancer - T. Sia
• Turning ProMisE into practice: Predicting response in medically managed endometrial cancers via molecular classification - A. Puechl
• Understanding Mechanisms of Disparities in Gynecologic Malignancies
• Universal Frontline PARP Maintenance: Just OK Is Not OK
• Upfront maintenance with anti-vascular versus PARP inhibitors in advanced ovarian cancer: A cost-effective analysis - M. Richardson
• Utilization of the emergency department by gynecologic oncology patients: high rates and high needs in a medically vulnerable population - D. Saris
• Video-assisted genetic counseling in patients with ovarian, fallopian, and peritoneal carcinoma
• Water only fasting and its effect on chemotherapy administration in gynecologic malignancies - C. Riedinger

Keywords: Allied health, Career development, Clinical trial, Clinical practice, Genetics, Telemedicine, Diversity & inclusion